Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology (EPIDOCAVILH)

17 de noviembre de 2026 actualizado por: Poitiers University Hospital

Pilot Study for the Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology

In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.

Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.

In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patient ≥ 18 years old.
  • Consultation for treatment initiation (first-line or relapse) for gynecological, digestive, urological, or hematological cancer.
  • Patient experiencing pain related to a cancer pathology (pain numerical rating scale ≥ 1) for less than 3 months.
  • Patient receiving outpatient cancer treatment at the Châtellerault site of Poitiers University Hospital.
  • Patient declaring having a general practitioner.
  • Patient's general practitioner agreeing to participate in the study.
  • Patient covered by the French social Security system or through a third party.

Non-Inclusion Criteria:

  • Patient already receiving care for this pain from the reference pain center or supportive care team.
  • Patient unable to understand, write, or speak French.
  • Patient diagnosed with uncontrolled psychiatric disorders.
  • Patient with chronic pain unrelated to cancer.
  • Pain related to therapeutic procedures.
  • Patient residing in a medicalized facility.
  • Patient under enhanced protection, including: minors, pregnant or breastfeeding women, individuals deprived of liberty by judicial or administrative decision, individuals staying in a healthcare or social institution, adults under legal protection (guardianship, curatorship, or subordination), patients in emergency situations.
  • Patient with a significant impairment of general condition (ECOG-PS > 2, Eastern Cooperative Oncology Group Performance Status) or cognitive disorders.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Early management of acute pain

Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP.

Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary.

Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms.

Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of eligible patients that provide a consent to participate
Periodo de tiempo: 1 day

Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent.

1 day
Proportion of general pactitioner that confirmed their participation
Periodo de tiempo: 2 days

General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation.

2 days
Proportion of consultations with the general practitioner performed
Periodo de tiempo: 28 days

Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed.

28 days
Proportion of consultations at the hospital performed
Periodo de tiempo: 28 days

Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed.

28 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in pain severity after 28 days
Periodo de tiempo: 28 days

Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain).

28 days
Change in pain interference after 28 days
Periodo de tiempo: 28 days

Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain).

28 days
Change in quality of life after 28 days
Periodo de tiempo: 28 days

Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life).

28 days
Proportion of patients requiring a specific pain management
Periodo de tiempo: 28 days

Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team.

28 days
Global satisfaction of the patients
Periodo de tiempo: 28 days

Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied")

28 days
Proportion of patients with a modified prescription by the general practitioner for analgesics treatments
Periodo de tiempo: 28 days

The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch

28 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

31 de enero de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

20 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • EPIDOCAVILH
  • 2026-A01683-48 (Otro identificador: French Ethics Committee Number (ID-RCB))

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .